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Prolactin (PRL) stimulates breast cancer cell pro-
liferation; however, the involvement of PRL-acti-
vated signaling molecules in cell proliferation is not
fully established. Here we studied the role of c-Src
on PRL-stimulated proliferation of T47D and MCF7
breast cancer cells. We initially observed that PRL-
dependent activation of focal adhesion kinase
(Fak), Erk1/2, and cell proliferation was mediated
by c-Src in T47D cells, because expression of a
dominant-negative form of c-Src (SrcDM, K295A/
Y527F) blocked the PRL-dependent effects. The
Src inhibitor PP1 abrogated PRL-dependent in vivo
activation of Fak, Erk1/2, p70S6K, and Akt and the
proliferation of T47D and MCF7 cells; Janus kinase
2 (Jak2) activation was not affected. However, in
vitro, Fak and Jak2 kinases were not directly inhib-
ited by PP1, demonstrating the effect of PP1 on
c-Src kinase as an upstream activator of Fak. Ex-
pression of Fak mutant Y397F abrogated PRL-
dependent activation of Fak, Erk1/2, and thymidine
incorporation, but had no effect on p70S6K and
Akt kinases. MAPK kinase 1/2 (Mek1/2) inhibitor
PD184352 blocked PRL-induced stimulation of
Erk1/2 and cell proliferation; however, p70S6K and
Akt activation were unaffected. The phosphatidyl-
inositol 3-kinase (PI3K) inhibitor LY294002 abol-
ished cell proliferation and activation of p70S6K
and Akt; however, PRL-dependent activation of
Erk1/2 was not modified. Moreover, we show that
both c-Src/PI3K and c-Src/Fak/Erk1/2 pathways
are involved in the up-regulation of c-myc and cy-
clin d1 expression mediated by PRL. The previous
findings suggest the existence of two PRL-depen-
dent signaling cascades, initiated by the c-Src-
mediated activation of Fak/Erk1/2 and PI3K path-
ways that, subsequently, control the expression of
c-Myc and cyclin D1 and the proliferation of T47D
and MCF7 breast cancer cells. (Molecular Endo-
crinology 17: 2268–2282, 2003)
THE INTERACTION OF PROLACTIN (PRL) with itsreceptor controls a variety of physiological func-
tions, including the proliferation of normal and tumor
mammary gland epithelium (for a review see Ref. 1).
The PRL receptor (PRLR) belongs to the cytokine/
hematopoietic receptor superfamily (2) and is devoid
of intrinsic enzymatic activity. Binding of PRL to the
PRLR activates the associated nonreceptor tyrosine
kinase Janus kinase 2 (Jak2) (3), which, in turn, phos-
phorylates the PRLR, generating docking sites for Src
homology domain 2 (SH2)-containing molecules and
stimulating signaling cascades such as Stats (Jak2-
signal transducers and activators of transcription) and
MAPK (Grb2/Sos-Ras-Raf-MAPK) (4–7). Activation of
Src kinases by PRL has been observed in different
experimental models including hepatocytes, PRLR-
transfected chicken embryo fibroblasts, and Nb2,
HC11, and W53 cell lines (8–12). More recently, a
critical role for Src kinases in PRL-dependent cell pro-
liferation (12) has been demonstrated in W53 cells (13).
Increasing evidence supports the involvement of
PRL in breast cancer. The PRLR is detected in 80% of
human breast cancer (14), and, in fact, is overex-
pressed in tumor cells of breast cancer samples (15).
Because normal and tumor mammary epithelial cells
synthesize PRL and its receptor (16, 17), the hormone
could behave as an autocrine growth factor for human
breast cancer cells. Consistent with the fact that PRL
is mitogenic in the majority of breast cancer cell lines
(18), PRL was shown to activate MAPK pathways in
T47D cells (19). Moreover, the expression of cyclin D1,
Abbreviations: DMSO, Dimethylsulfoxide; ECL, enhanced
chemiluminescence; Fak, focal adhesion kinase; FCS, fetal
calf serum; HA, hemagglutinin; Jak2, Janus kinase 2; mAb,
monoclonal antibody; Mek, MAPK kinase; PI3K, phosphati-
dylinositol 3-kinase; PRL, prolactin; PRLR, PRL receptor;
SDS, sodium dodecyl sulfate; SH2, Src homology domain 2;
Stat, signal transducer and activator of transcription; TBS,
Tris-buffered saline; TTBS, TBS with 0.05% Tween 20; WB,
Western blot.
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required for G1/S cell cycle transition, was shown to be
regulated by PRL in MCF7 cells (20).
Recent findings demonstrate that migration of
breast cancer cells is enhanced by PRL (21). Focal
adhesion kinase (Fak), localized at focal contacts, is
involved in the control of cellular responses, such as
cell spreading, migration, survival, and proliferation
(22–24). Integrin-induced autophosphorylation of Fak
at Y397 generates a SH2 binding site for c-Src and Fyn
Src kinases (25, 26). Phosphorylation of additional
sites in Fak by the Src kinases (27) regulates its cat-
alytic activity and enables the association of docking
proteins such as Cas, paxillin, and the Grb2-Sos com-
plex, and consequently links the Fak and Ras/MAPK
pathways (28, 29). This could be the mechanism un-
derlying the control of cyclin D1 expression and cell
cycle progression by Fak (30). Moreover, Fak is acti-
vated by the v-Src oncogene (31) and cell surface
receptors, such as PRLR (32). Interestingly, some bi-
ological effects of PRL in mammary gland epithelium
are mediated by interactions with the extracellular ma-
trix (33). These data suggest that phosphorylated Fak
integrates multiple transduction pathways in response
to external signals provided by the extracellular matrix
and growth factors.
Additional pathways, such as phosphatidylinositol
3-kinase (PI3K) (34), required for proliferation of W53
cells (12), have also been implicated in PRL-induced
cell proliferation.
Involvement of c-Src in malignant transformation of
mammary gland epithelium is suggested by the in-
creased c-Src kinase activity found in breast carcino-
mas (35), and because functional c-Src is required for
the induction of mammary tumors by polyomavirus
middle T antigen (36). Furthermore, transgenic mice
expressing constitutively activated c-Src (Y527F), un-
der the control of the mouse mammary tumor virus
promoter/enhancer, show increased hyperplasia of
mammary gland epithelium, which eventually gener-
ates tumors (37). Similarly, expression of oncogenic
Src in human breast cancer cell MCF7 activates cyclin
D1 expression (38).
Notwithstanding available data implicating PRL in
breast cancer pathogenesis and progression, how-
ever, the timely regulation of the downstream targets
that mediate these effects has not been clearly estab-
lished. In this study we have investigated the func-
tional role of Src on PRL-dependent stimulation of
T47D and MCF7 cell proliferation. Our results show
that activation of c-Src by PRL leads to the indepen-
dent stimulation of Fak-Erk1/2 and PI3K signaling
pathways, which are required for the induction of c-
myc and cyclin d1 expression and the proliferation of
T47D and MCF7 human breast cancer cells.
RESULTS
To confirm the mitogenic activity of PRL, cells were
maintained for 3 d in serum-free, phenol red-free
DMEM. Addition of PRL to nonstimulated cultures of
T74D (5 104 cells) increased thymidine incorporation
in a concentration-dependent manner. Maximal stim-
ulation, 2.2-fold over basal levels (12,280  1,283
cpm), was observed at 100 ng/ml, reaching a plateau
(Fig. 1A). This concentration was subsequently used
for further experiments. Under these conditions, no
apoptosis was detected by flow cytometry analysis of
propidium iodide-labeled cells (data not shown).
Considering that Src kinases are activated by PRL in
a variety of cell types (8–12), we analyzed the role of
these tyrosine kinases in the induction of T47D cell
proliferation by PRL. First, we analyzed the expression
pattern of Src kinases activated by PRL in T47D cells.
We observed that c-Src, Fyn, Yes, and Blk were ex-
pressed in T47D cells, as determined by Western blot
(WB) analysis of cell extracts with monospecific
antibodies (data not shown). Kinase activity was sub-
sequently studied, at different time points, by immu-
noprecipitation of c-Src, Fyn, Yes, and Blk from PRL-
stimulated (100 ng/ml) cells. Next, the immune
complexes were subjected to in vitro 32P autophos-
phorylation assays. We observed that only c-Src auto-
phosphorylation/activation was induced by PRL. The
1.8-fold activation above basal levels was transient
and peaked at 5 min after stimulation of T47D cells
with PRL (Fig. 1B).
Src kinases have been previously reported to con-
trol Fak activation (39–41). To determine the role of
Src kinases on PRL-dependent stimulation of T47D
cell proliferation and Fak activation, we initially per-
formed in vitro 32P autophosphorylation assays with
Fak immunoprecipitates from cells stimulated with
PRL (100 ng/ml) at different times. PRL induced a
2-fold transient activation of Fak above basal levels
at 10 min (Fig. 1B). Moreover, to evaluate the effect
of PRL stimulation on Fak tyrosine phosphorylation
in T47D cells, nonstimulated cells were treated with
increasing amounts of PRL for 15 min. Fak phos-
phorylation was determined in anti-Fak immunopre-
cipitates by WB with antiphosphotyrosine 4G10
monoclonal antibody (mAb). The results show that
maximal phosphorylation of Fak was reached with
50–100 ng/ml of PRL (Fig. 1C). Then, we determined
the kinetics of Fak tyrosine phosphorylation after
stimulation with PRL (100 ng/ml). Fak phosphoryla-
tion was detected at 5 min after PRL addition,
reached maximal levels after 15 min of stimulation,
and decreased at 45 min (Fig. 1D). We subsequently
studied the effect of PRL stimulation (100 ng/ml for
15 min) on tyrosine phosphorylation of paxillin in
T47D cells, currently considered a substrate of Fak.
Thus, paxillin was immunoprecipitated, and its
phosphotyrosine (pY) content was determined by
WB with mAb 4G10. As shown in Fig. 1E, PRL
stimulated the phosphorylation of paxillin (Fig. 1E).
Stimulation by PRL is known to activate Erk1/2 in
many cell types (1). Addition of PRL (100 ng/ml, 15
min) to nonstimulated T47D cultures resulted in Erk1/2
activation, as determined by WB with phospho-
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specific antibodies defining Erk1/2 activation status
(Fig. 1F). As previously observed for Fak and paxillin,
basal levels of Erk1/2 activation were detected in T47D
nonstimulated cells.
To evaluate the role of c-Src in PRL-mediated sig-
naling events leading to the proliferation of T47D cells,
we performed transient transfection with the domi-
nant-negative c-Src kinase (SrcDM). As shown in Fig.
Fig. 1. Effect of PRL on Proliferation of T47D Cells: Modulation of Fak, c-Src, and Erk1/2 Kinase Activities and Tyrosine
Phosphorylation of Fak and Paxillin by PRL
A, T47D cells were seeded in 24-well plates (5  104 cells per well) in DMEM-phenol red-free-10% FCS. After 24 h, they were
transferred to serum-free media for 48 h, cultured in the presence of increasing concentrations of PRL for 72 h, and pulsed with
0.5 Ci [3H]thymidine/well for the final 4 h. Thymidine incorporation was measured as described in Materials and Methods. B,
c-Src and Fak were immunoprecipitated using 500 g of protein extract from cells stimulated with PRL (100 ng/ml) for 0, 5, 10,
and 20 min. The immune complexes were subjected to autophosphorylation reactions and separated by 7% SDS-PAGE, and the
radioactivity in the c-Src and Fak proteins was measured using an Instantimager, as described in Materials and Methods. The
results are expressed as fold increase above basal levels. Resting cells were treated with increasing concentrations of PRL (0,
25, 50, 100, and 200 ng/ml) for 15 min (panel C) or for different time periods (0, 5, 15, 20, and 45 min) with PRL (100 ng/ml) (panel
D). Fak was immunoprecipitated (IP) from 500 g of protein extract and tyrosine phosphorylation was determined by WB with
4G10 antiphosphotyrosine mAb. E, Paxillin IP was performed with 500 g protein extract from resting or PRL-stimulated (100
ng/ml, 15 min) cells, and the phosphotyrosine (pY) content was determined by WB with mAb 4G10. F, Erk1/2 activation was
measured with 25 g of protein extract from resting or PRL-stimulated (100 ng/ml, 15 min) cells by WB with anti-phospho-Erk1/2
antibodies. Lower panels show the stripped membranes reprobed with the antibody used for immunoprecipitation (C, D, and E)
or with anti-Erk2 (F). The data are representative of three separate experiments. In panel A, control cell (nonstimulated) values are
given as the unit for cell proliferation. The data presented are the mean  SE (bars) of three independent experiments carried out
in triplicate. The asterisk (*) represents P  0.05 compared with the control group in the Student’s t test.
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2A, transfection of T47D cells with SrcDM resulted in
high expression of the mutant protein, inhibiting PRL-
induced [3H]thymidine incorporation below basal lev-
els (Fig. 2B) and reducing the phosphorylation of Fak
and Erk1/2 induced by PRL (Fig. 2, C and D). The
selective inhibitor of Src kinases PP1 (42, 43) blocked
the in vitro kinase activity associated with Src immu-
noprecipitates (Fig. 3A); 1 M PP1 inhibited the auto-
phosphorylation of c-Src induced by PRL. However,
Fak autocatalytic activity was not affected, at concen-
trations as high as 2.5 M (Fig. 3B). Because Jak2
activation is considered a key element in PRL cell
signaling (1) and is required for PRL mitogenic activity
in mouse mammary gland epithelial HC11 cells (44),
we tested the effect of Src inhibition on the activation
of Jak2 by PRL. The in vitro autophosphorylation as-
say for Jak2 was performed in the presence of increas-
ing PP1 concentration. As shown in Fig. 3C, PP1 con-
Fig. 2. Effect of SrcDM Expression on PRL-Induced Cell
Proliferation and Fak and Erk1/2 Activation in T47D Cells
T47D cells were transiently transfected with either pSGT-
SrcDM or the empty vector (Vo) and stimulated with PRL (100
ng/ml, 15 min). A, Protein extracts (25 g) were separated on
9% SDS-PAGE, and WB analysis was performed with anti-
c-Src antibody. B, Thymidine incorporation was calculated as
in Fig. 1. C, Fak was immunoprecipitated from 500 g of
protein extract with anti-Fak and its phosphotyrosine (pY)
content determined by WB with mAb 4G10. D, Activation of
Erk1/2 was evaluated as in Fig. 1F. In panel B, values are
presented as the mean  SE (bars) of three independent
experiments carried out in triplicate. The asterisk (*) repre-
sents P  0.05 compared with the control group (Vo) in
Student’s t test (n  3). The data in panels C and D are
representative of three separate experiments.
Fig. 3. Effect of Src Inhibitor PP1 on PRL-Induced Activation
of c-Src, Fak, and Jak2
c-Src (panel A), Fak (panel B), and Jak2 (panel C) were
immunoprecipitated (IP) from 500 g of protein extract of
T47D cells stimulated with PRL (100 ng/ml) for 5 min, and 10
min for Fak, and then subjected to autophosphorylation (Au-
to-P) reactions for 5 min in the presence of increasing con-
centrations of PP1 (0, 0.1, 1, and 2.5 M). Reaction mixtures
were subjected to 7% SDS-PAGE, and dried gels exposed to
x-ray film to detect 32P-labeled proteins. Results are repre-
sentative of four separate experiments. D, T47D cells were
incubated in the presence of DMSO (control) or PP1 (2.5 M,
2 h) before the addition of PRL (100 ng/ml, 15 min). Jak2 was
immunoprecipitated from 500 g of protein extract with spe-
cific antibodies, and tyrosine phosphorylation was detected
by WB with mAb 4G10. Lower panel shows the stripped
membrane reprobed with anti-Jak2 antibody. The results are
representative of two independent experiments.
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Fig. 4. Effect of the Src Inhibitor PP1 on PRL-Induced Cell Proliferation and Activation of Fak, Erk1/2, p70S6K, and Akt in T47D
and MCF7 Cells
A, T47D and MCF7 cells were seeded in 24-well plates (5  104 cells per well) in DMEM-10% FCS and 24 h later transferred
to serum-free media for 48 h. Subsequently, cells were incubated in the absence or presence of PRL (100 ng/ml) and/or PP1 (1
M) for 72 h, and pulsed with 0.5 Ci [3H]thymidine/well for the final 4 h. Thymidine incorporation was measured as described
in Materials and Methods. Src inhibition by PP1 on PRL-mediated activation of Fak, Erk1/2, p70S6K, and Akt was analyzed by
incubating resting cells in the presence of DMSO (control) or PP1 (1 M) for 2 h before the addition of PRL (100 ng/ml, 15 min).
B, Fak was immunoprecipitated from cell extracts and immune complexes were subjected to 7% SDS-PAGE and WB analysis
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centrations up to 2.5 M, which abrogated c-Src
activity, were unable to modify the auto-phosphoryla-
tion of Jak2. We next determined the involvement of
c-Src on PRL-dependent activation of Jak2 in T47D
cells. Addition of PRL (100 ng/ml for 15 min) increased
tyrosine phosphorylation of Jak2, and PRL-dependent
activation of Jak2 was unaffected by pretreatment of
cells with PP1 (2.5 M) (Fig. 3D). Similar results were
obtained by transient expression of SrcDM in T47D
cells (data not shown).
To investigate the involvement of c-Src in PRL-
dependent mitogenic signaling in breast cancer cells,
T47D and MCF7 cell lines were treated with 1 M PP1.
As shown in Fig. 4A, PP1 inhibited both basal and
PRL-induced proliferation in these cells. Subse-
quently, we analyzed the role of c-Src in the control of
PRL-dependent signaling pathways in the presence of
1 M PP1. We observed that addition of PRL (100
ng/ml for 15 min) to nonstimulated T47D and MCF7
cells increased the phosphorylation/activation of Fak,
Erk1/2, and PI3K-dependent serine/threonine kinases
p70S6K and Akt (Fig. 4, B–E) and was inhibited by
treatment of T47D and MCF7 cells with PP1 before
PRL stimulation, demonstrating that c-Src mediates
the activation of these kinases by PRL (Fig. 4, B–E).
Direct phosphorylation of Fak by c-Src (27) facili-
tates the activation of the MAPK pathway (40, 45).
Therefore, to investigate the role of Fak in PRL-stim-
ulated cell proliferation, we obtained T47D and MCF7
cell lines expressing Fak Y397F mutant tagged with an
hemagglutinin (HA) epitope (Fak-F397) (Fig. 5A). As
shown in Fig. 5B, expression of the mutant blocked
PRL-induced [3H]thymidine incorporation in both cell
lines.
The functional effect of Fak-F397 expression on the
activation of Fak phosphorylation by PRL was further
studied by WB detection with mAb 4G10 in Fak im-
munoprecipitates from resting and PRL-stimulated
T47D and MCF7 cells. We show that PRL increases
Fak phosphotyrosine content (Fig. 4B) and that the
expression of Fak-F397 abrogates this effect in both
cell lines (Fig. 5C). Moreover, expression of the Fak
mutant abolished the previously observed activation
of Erk1/2 by PRL (Fig. 5D). In contrast, Fak-F397 had
no effect on the stimulation of the PI3K pathway by
PRL, because phosphorylation of both p70S6K and
Akt was increased upon stimulation of Fak-F397
T47D- and MCF7-expressing cells by PRL (Fig. 5, E
and F, respectively). These results evidence the sig-
nificance of Fak activation in mediating Erk1/2 activa-
tion and T47D and MCF7 cell proliferation induced by
PRL and demonstrate that the PRL-stimulated PI3K
pathway is independent of Fak activation.
The previous data suggest the involvement of
MAPKs in the control of T47D and MCF7 proliferation
induced by PRL. Thus, to evaluate their contribution to
PRL-mitogenic signaling, both cell lines were treated
with PD184352 (1 M), a selective inhibitor of Mek1/2
(MAPK kinase) activity (46). PD184352 decreased both
basal and PRL-stimulated levels of [3H]thymidine in-
corporation (Fig. 6A). Moreover, PD184352 treatment
abolished basal and PRL-induced Erk1/2 activation
levels in both T47D and MCF7 cells (Fig. 6B). However,
interference of the MAPK signaling pathway did not
affect PRL-induced p70S6K and Akt phosphorylation
(Fig. 6, C and D).
To evaluate the relevance of PI3K-dependent sig-
naling pathways in the induction of T47D and MCF7
cell proliferation by PRL, the PI3K-selective inhibitor
LY294002 (10 M) was used. The results show that
inhibition of PI3K activity with LY294002 abolished
basal and PRL-stimulated T47D and MCF7 cell prolif-
eration (Fig. 7A). In addition, stimulation of p70S6K
and Akt phosphorylation by PRL was inhibited by
LY294002 below basal levels (Fig. 7, B and C). In
contrast, Erk1/2 phosphorylation induced by PRL re-
mained unaltered when PI3K activity was inhibited
(Fig. 7D). We observed no inhibitory effect of
PD184352 and LY294002 on the activation of c-Src
and Fak by PRL (data not shown).
The aforementioned PRL-stimulated mitogenic sig-
naling cascades should ultimately induce the expres-
sion of c-myc and cyclin d1, critical molecules for G1/S
cell cycle progression. We therefore evaluated
whether PRL activation of c-Src and the subsequent
stimulation of the PI3K and/or the Erk1/2 pathways
were required for the control of c-myc and cyclin d1
expression in T47D and MCF7 cells. Thus, cells were
stimulated with 100 ng/ml PRL for different time peri-
ods in the presence or absence of PP1, PD184352, or
LY294002, and mRNA expression of c-myc and cyclin
d1 was determined by Northern analyses from 16 g
of total RNA with specific probes. As shown in Fig. 8A,
c-myc and cyclin d1 mRNA levels were increased by
PRL in T47D and MCF7 cells. Interestingly, we showed
that c-Src and the c-Src-dependent PI3K and Erk1/2
pathways are critical mediators of PRL in the up-
regulation of mRNA expression of c-myc and cyclin
d1, as demonstrated by the down-regulation in gene
expression due to selective inhibition of these kinases
(Fig. 8A). Similar results were obtained when the ex-
with mAb 4G10. Activation of Erk1/2 (panel C), p70S6K (panel D), and Akt (panel E) was analyzed by WB with anti-phospho-
specific antibodies in 25 g protein extracts from resting or PRL-stimulated (100 ng/ml, 15 min) cells. Lower panels show the
stripped membranes reprobed with the corresponding antibodies (panels B, C, D, and E) for total specific protein. The data are
representative of three separate experiments. For thymidine incorporation (panel A), values are presented as the mean SE (bars)
of three independent experiments carried out in triplicate. The asterisk (*) represents P  0.05 compared with the control group
in Student’s t test.
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Fig. 5. Effect of Fak-F397 Expression on PRL-Induced Cell Proliferation and the Activation of Fak, Erk1/2, p70S6K, and Akt
Induced by PRL in T47D and MCF7 Cells
T47D (left panels) and MCF7 (right panels) cells were transfected with pcDNA3 (Vo) or HA-tagged pcDNA3-FakF397, selected
with G418 (2 mg/ml), and tested for expression of the Fak mutant. A, Protein extracts (25 g) were separated by 7% SDS-PAGE
and WB was performed with anti-HA. Tubulin was detected for loading control. B, The effect of Fak-F397 expression in
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pression of c-myc and cyclin d1 was analyzed by WB
(Fig. 8B).
DISCUSSION
PRL involvement in breast cancer has been clearly
established (20); however, the sequential stimulation
of elements involved in signaling cascades that lead to
cell proliferation has not been fully demonstrated. Here
we describe that addition of PRL to T47D and MCF7
epithelial human breast cancer cells determines the
activation of Src kinases, which, independently, stim-
ulate: 1) the activation of Fak/Erk1/2 and the PI3K-
dependent p70S6K and Akt kinases, 2) the up-regu-
lation of c-myc and cyclin d1 mRNA expression and 3)
cell proliferation.
The moderate activation of signaling molecules and
cell proliferation over basal levels induced in T47D and
MCF7 by PRL may be due to the tumor status of these
cells. Breast cancer cells normally produce PRL and
PRLR (16, 47), among other growth factors, which by
an autocrine/paracrine feedback loop allow their
growth in serum-free media. In this context, it has
been recently shown that addition of PRL to MCF7
cells induced a slight increase in proliferation (20). The
differences in the basal levels of activation of the sig-
naling molecules analyzed in this study should be con-
sidered as experimental variability among the different
experiments performed. However, we consider that
increased phosphorylation induced by PRL is clearly
detected even with high background levels (e.g. Figs.
1F, 4C, 5F, 6B, and 7D). As previously considered for
basal phosphorylation levels, the different effect of
PI3K, Erk1/2, and Src inhibitors on basal cell prolifer-
ation may be explained by the endogenous production
of growth factors by tumor cells that initiate diverse
signaling pathways involving these kinases.
Activation of Src kinases by PRL occurs in a variety
of cells (8–12). c-Src, Fyn, Yes, and Blk are the Src
kinases expressed in T47D cells (data not shown);
however, c-Src is the only member activated by PRL.
The degree of c-Src activation (1.8 fold) induced in
T47D cells by PRL is similar to that observed in other
experimental models (8–12). In addition, abrogation of
c-Src function, by overexpression of SrcDM or its
inhibitor PP1 (42, 43), blocked PRL-dependent cell
proliferation and down-regulated the activity of
growth-related signaling molecules, such as Fak,
Erk1/2, and the PI3K-dependent p70S6K and Akt ki-
nases below basal levels. In contrast, inhibition of
c-Src function did not affect the activation of Jak2 by
PRL. The fact that Src kinases are stimulated by a
variety of growth factors and cytokines (48–50), and
that breast cancer cells synthesize their own growth
factors, may help to maintain a certain level of c-Src
activation, which, in turn, could account for the resid-
ual activity of signaling molecules and the proliferation
rate encountered in the absence of exogenous PRL.
Here we observed that PP1 abolished c-Src activity
both in vivo and in vitro, as was previously reported
(42, 43). However, PP1 was unable to block PRL-
stimulated Fak autophosphorylation in vitro. There-
fore, the inhibition of Fak phosphorylation mediated by
PP1 observed in T47D and MCF7 PRL-stimulated
cells is not a direct effect on Fak, but a consequence
of c-Src inhibition, which phosphorylates Fak. Phos-
phorylation of Fak on Y925 by c-Src recruits SH2-
Grb2, resulting in the activation of the Sos-Ras-Raf-
Mek-Erk pathway (28, 29). Our results demonstrate
that overexpression of Fak-F397 in T47D and MCF7
cells abolishes the activating effect of PRL on Fak,
Erk1/2 phosphorylation and cell proliferation, but does
not affect PRL stimulation of the PI3K-dependent
p70S6K and Akt kinases. These data are in agreement
with reports showing that Y397F mutation disrupts
c-Src binding and reduces Fak phosphotyrosine con-
tent (29). Breast cancer tumors have increased c-Src
and MAPK activities (35, 51); moreover, the participa-
tion of the c-Src/Ras/MAPK pathway in T47D cell
growth has been proposed (52). Our results show that
activation of Erk1/2 by PRL is correlated with in-
creased proliferation of T47D and MCF7 cells, consid-
ering that the inhibition of PRL-activated Erk1/2 by the
Mek1 inhibitor PD184352 reduces T47D and MCF7
proliferation. Similar results were obtained with other
MAPK pathway inhibitors (PD98059, U0126) (data not
shown). These observations are consistent with the
correlation between PRL stimulation of Erk1/2 and
enhanced proliferation of T47D cells (19). Furthermore,
our data suggest that Erk1/2 activation by PRL in
these cell lines is mediated by c-Src/Fak because it is
abrogated by c-Src inhibition and by expression of the
Fak-F397 mutant. It is noteworthy that, whereas PRL
activation of Erk1/2 is mediated by c-Src in epithelial
human breast cancer cells (T47D and MCF7), in the
mouse hematopoietic W53 cell line the activation of
Erk1/2 by PRL is independent of Src kinases, because
PP1 has no effect (12). Therefore, the previous data
imply that PRL mitogenic signaling cascades are cell
type dependent.
PRL-induced thymidine incorporation in T47D and MCF7 cells was carried out as in Fig. 4. C, Fak was immunoprecipitated from
500 g of protein extract with anti-Fak antibodies, and tyrosine phosphorylation was determined by WB with mAb 4G10.
Activation of Erk1/2 (D), p70S6K (E), and Akt (F) was measured by WB with anti-phospho-specific antibody using 25 g of protein
extracts from resting or PRL-stimulated (100 ng/ml, 15 min) cells. Lower panels show the stripped membranes reprobed with the
corresponding antibodies (C, D, E, and F) for total specific protein. The data are representative of three separate experiments.
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Jak2 is a relevant mediator of PRL mitogenic sig-
naling in T47D cells (32). In this work we show that
PP1, at concentrations that block Src kinase activity,
was unable to alter activation of Jak2 by PRL in vivo
and in vitro; similar results were obtained in W53 cells
(12). These findings suggest that Src kinases could be
engaged in PRL signal transduction either down-
stream of PRLR dimerization and Jak2 activation or in
a Jak2-independent pathway. In this context, we have
previously reported that, in chicken embryo fibro-
blasts, c-Src activation by PRL is independent of Jak2
because a PRLR mutant, unable to interact and acti-
vate Jak2, could still mediate the activation of c-Src
(11). Moreover, the participation of Fak in the activa-
tion of Jak2 by PRL could be excluded, considering
that PP1 inhibits PRL stimulation of Fak activity with-
out affecting Jak2 phosphorylation. Although in Chi-
nese hamster ovary cells transfected with the GH re-
Fig. 6. Effect of the Mek1/2 Inhibitor PD184352 on Cell Proliferation and Activation of Fak, Erk1/2, p70S6K, and Akt Induced by
PRL in T47D and MCF7 Cells
A, The effect of PD184352 (1 M) on PRL-induced thymidine incorporation in T47D and MCF7 cells was carried out as in Fig.
4. The effect of Mek1/2 inhibition by PD184352 (1 M) in the activation of Fak, Erk1/2, p70S6K, and Akt mediated by PRL was
carried out as in Fig. 4. Activation of Erk1/2 (B), p70S6K (C), and Akt (D) was measured by WB with anti-phospho-specific
antibodies using 25 g of protein extract from resting or PRL-stimulated (100 ng/ml, 15 min) cells. Lower panels show the stripped
membranes reprobed with their corresponding antibodies (B, C, and D) for total specific protein. The data are representative of
three separate experiments. For thymidine incorporation (A), values are presented as the mean  SE (bars) of three independent
experiments carried out in triplicate. The asterisk (*) represents P  0.05 compared with the control group in Student’s t test.
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ceptor, Fak coimmunoprecipitates with Jak2 upon
hormone stimulation (53), our data indicate that in
T47D and MCF7 cells, Src and Fak activities are not
required for the activation of Jak2 by PRL.
It has been previously demonstrated that expres-
sion of c-myc and cyclin d1 is required for cell prolif-
eration. In this work we observed that proliferation of
T47D and MCF7 cells stimulated by PRL is associated
with the up-regulation of c-myc and cyclin d1 expres-
sion. Moreover, the data we present support the fact
that c-Src, by regulating both Fak/Erk1/2 and PI3K
PRL-stimulated pathways, controls the expression of
c-myc and cyclin d1 (Fig. 8). Consistently, we have
previously shown that PRL-stimulated c-myc expres-
sion was regulated by Src kinases in W53 cells (12).
The involvement of Src in cyclin d1 expression was
Fig. 7. Effect of the PI3K Inhibitor LY294002 on Cell Proliferation and Activation of Fak, Erk1/2, p70S6K, and Akt induced by PRL
in T47D and MCF7 Cells
A, The effect of LY294002 (LY) (10 M) on PRL-induced thymidine incorporation in T47D and MCF7 cells was carried out as
in Fig. 4. The effect of PI3K inhibition by LY294002 (10 M) on the activation of Fak, Erk1/2, p70S6K, and Akt by PRL was carried
out as in Fig. 4. Activation of p70S6K (B), Akt (C), and Erk1/2 (D) was determined by WB with anti-phospho-specific antibodies
using 25 g of protein extracts from resting or PRL-stimulated (100 ng/ml, 15 min) cells. Lower panels show the stripped
membranes reprobed with the corresponding antibodies (B, C, and D) for specific total protein. The data are representative of
three separate experiments. For thymidine incorporation (A), values are presented as the mean  SE (bars) of three independent
experiments carried out in triplicate. The asterisk (*) represents P  0.05 compared with the control group in Student’s t test.
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demonstrated in breast cancer cells, because expres-
sion of the oncogenic form of Src (v-Src) activated the
promoter cyclin d1 in MCF7 cells (38). Regarding the
control of cyclin d1 expression due to signal transduc-
tion via activation of Fak/Erk1/2 by Src, it was reported
that activation of Fak by integrins resulted in increased
transcription of cyclin d1 via the activation of the
Erk1/2 pathway (30). Further results obtained with
MCF7 cells implicate the Jak2/Stat5 pathway in the
increase of cyclin d1 expression observed upon stim-
ulation with PRL (54). The previous data indicate that,
in addition to the -interferon-activated sequence
sites regulated by the Jak2/Stat5 pathway (54), the
cyclin d1 promoter also contains Fak/Erk1/2 pathway-
responsive EtsB binding sites (30). Our results dem-
onstrate that PRL, via c-Src, activates PI3K-depen-
dent Akt and p70S6K serine/threonine kinases and
cyclin d1. Akt is involved in regulating cyclin D1 ex-
pression in mammary tumors developed by transgenic
mice for middle T antigen (55). Consistent with this
report, ectopic expression of phosphatase and tensin
homolog on chromosome 10 (PTEN) in MCF7 cells
blocks Akt activation and cyclin d1 expression (56).
Moreover, PI3K-p70S6K kinase has been similarly im-
plicated in the control of cyclin d1 expression because
rapamycin was shown to inhibit p70S6K and cyclin d1
expression in vascular endothelial cells (57).
The data presented here show that addition of PRL
to T47D and MCF7 cells results in the activation of
c-Src, Fak/Erk1/2, PI3K-dependent p70S6K and Akt
pathways, c-myc and cyclin d1 expression, and in-
creased cell proliferation, and abrogation of c-Src ac-
tivity inhibits all the events. Fak-F397 mutation or in-
hibition of MAPKs with PD184352 was unable to
modify the activation of PI3K; furthermore, inhibition of
PI3K by LY294002 did not affect the Fak/Erk1/2 path-
way. However, both pathways are required for c-myc
and cyclin d1 expression and enhanced cell prolifera-
tion. In conclusion, our results report that regulation of
c-Src/Fak/Erk1/2 and c-Src/PI3K cell-signaling path-
ways is mediated by c-Src when T47D and MCF7
breast cancer cells are stimulated with PRL, and, in
turn, they regulate c-myc and cyclin d1 expression and
cell proliferation (Fig. 9). It is clearly established that
Src kinases are mediators of multiple factors involved
in proliferation, angiogenesis, and migration of breast
cancer cells. Thus, Src kinases may represent relevant
targets in breast cancer therapy.
Fig. 8. Effect of the Src Inhibitor PP1, the Mek 1/2 Inhibitor PD184352 (PD), and the PI3K Inhibitor LY294002 (LY), on
PRL-Mediated Expression of c-myc and cyclin d1 in T47D and MCF7 Cells
T47D (left panels) and MCF7 (right panels) cells were seeded in DMEM-10% FCS and 24 h later transferred to serum-free
medium for 72 h. Resting cells were incubated in the absence or presence of PP1 (1 M), PD 184352 (1 M), or LY294002 (10
M) for 2 h before stimulation with PRL (100 ng/ml) for the indicated time periods (h). The expression of c-myc and cyclin d1 was
determined by Northern blotting using 16 g of RNA extracts (panel A) and WB using 25 g of protein extracts (panel B), as
described in Materials and Methods. A positive control of RNA (16 g) and protein cell extracts (25 g) was included on each blot
(C). Positive controls for c-myc Northern and Western blots consist of total RNA and protein extracts from T47D and MCF7 cells
stimulated with 10% serum for 1 h. The positive controls for cyclin D1 Northern and Western blots are total RNA and protein
extracts from T47D and MCF7 cells stimulated with 10% serum for 3 h. The data are representative of three separate experiments.
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MATERIALS AND METHODS
Materials
Ovine PRL (NIDDK-oPRL-20, 31 IU/mg) was kindly pro-
vided by the National Hormone and Pituitary Program of
the National Institute of Diabetes and Digestive and Kidney
Diseases (Bethesda, MD). Mouse mAb 327 against c-Src
was a gift from J. S. Brugge (Harvard University, Boston,
MA). Antiphosphotyrosine mAb 4G10 was obtained from
Upstate Biotechnology, Inc. (Lake Placid, NY). Affinity-
purified rabbit polyclonal antibodies to Src kinases (SRC-
2), Erk2 (C14), Fak (A17), Akt (H-136), and Jak2 (C20) were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Antipaxillin was purchased from Transduction Labo-
ratories, Inc. (Lexington, KY). Anti-p70S6K was obtained
from George Thomas (Friedrich Mistier Institute, Basel,
Switzerland). Antiphospho antibodies to pErk1/2,
pp70S6K, and pAkt are from New England Biolabs (Bev-
erly, MA). Secondary horseradish peroxidase-conjugated
antibodies were purchased from Biosource International
(Camarillo, CA). The enhanced chemiluminescence (ECL)
kit, radiochemicals, and the oligolabeling kit were from
Amersham Pharmacia Biotech (Buckinghamshire, UK).
PP1/PP2 were obtained from Alexis Biochemicals (San
Diego, CA). PD98059 and U0146 were obtained from Cal-
biochem (San Diego, CA). PD184352 was a gift from Philip
Cohen (MRC Protein Phosphorylation Unit, University of
Dundee, Dundee, Scotland, United Kingdom). Protein G-
Sepharose and protein A-Sepharose, Tri Reagent, and
other reagents were purchased from Sigma-Aldrich Corp.
(St. Louis, MO).
Cell Culture and Transfection
T47D cells were routinely grown in DMEM supplemented
with 10% fetal calf serum, 0.1 IU/ml insulin, 2 mM glu-
tamine, 100 IU/ml penicillin, and 100 g/ml streptomycin in
a humidified atmosphere containing 5% CO2 and 95% air
at 37 C. The pSGT plasmid containing the cDNA for the
dominant-negative mutant of c-Src, SrcDM (K295A/
Y527F), was obtained from S. Roche (Centre de Recherche
de Biochimie Macromole´culaire-Centre National de la Re-
cherche Scientifique, Unite´ Propre de Recherche 1086
France; Ref. 58). Exponentially growing T47D cells (5  106
cells) were transiently transfected using the calcium phos-
phate precipitation method with 60 g of pSGT-SrcDM. As
a control, T47D cultures were transfected with 60 g of the
pSGT empty vector. After 6 h incubation with the DNA
precipitates, cells were washed with DMEM and incubation
proceeded for an additional 24-h period. T47D-Fak-F397
and MCF7-Fak-F397 cell lines were generated by trans-
fection using Transfast reagent (Promega Corp., Madison,
WI). The Fak mutant Y397F cloned into pcDNA3-Fak-F397
(5 g) (D. Schlaepfer, Scripps Research Institute, La Jolla,
CA) was mixed with 5 l of Transfast in 2 ml of culture
media for 10 min at room temperature and added to the
cell plate (5  106 cells). After incubation at 37 C for 1 h,
8 ml of complete medium were added and incubation
proceeded for an additional 12 h. Cultures were then
washed twice with DMEM containing 10% fetal calf serum
(FCS), and cultured for 48 h before selection with G418 (2
mg/ml). Two weeks later, the concentration of G418 was
reduced to 1 mg/ml and fixed as the concentration for cell
culture.
Fig. 9. Role of c-Src in PRL-Induced Proliferation of T47D and MCF7 Cells
PRL induces dimerization of PRLR and activation of c-Src, which mediates the activation of PI3K/Akt/p70S6K and Fak/Erk1/2
signaling cascades, providing signals for c-Myc and cyclin D1 expression, required for cell proliferation. Our results show that PRL
activation of Jak2 is independent of c-Src. Grb2, Adaptor protein with SH2 and SH3 domains; mTOR, mammalian target of
rapamycin; PDKs, phospholipid-dependent kinase; PH, pleckstrin domain; SOS, Son of Sevenless.
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Immunoprecipitation and WB Analysis
Cells (1 106 cells per dish) for immunoprecipitation and WB
analysis were maintained in phenol red-free and serum-free
DMEM 72 h before stimulation with PRL. Subsequently, cells
were washed twice in ice-cold Tris-buffered saline (TBS: 20
mM Tris-HCl, pH 7.6; 140 mM NaCl) with 0.1 mM Na3VO4 and
lysed at 4 C in 1 ml of lysis buffer (10 mM Tris-HCl, pH 7.6; 50
mM NaCl; 30 mM sodium pyrophosphate; 5 mM EDTA; 0.5%
Nonidet P-40; 1% Triton X-100; 50 mM NaF; 0.1 mM Na3VO4;
1 mM phenylmethylsulfonylfluoride; 1 mM benzamidine; 1 mM
iodoacetamide; 1 mM phenantroline). Cell lysates were ob-
tained by centrifugation at 17,000  g for 15 min at 4 C,
protein concentration in the supernatant was determined by
BCA protein assay (Pierce Chemical Co., Rockford, IL), and
lysates were adjusted to equivalent concentrations with lysis
buffer. Immunoprecipitation was performed by incubating
lysates (500 g/ml of protein) with 1–2 g of the appropriate
specific antibody for 2 h at 4 C. Immune complexes were
recovered with protein G-Sepharose or protein A-Sepharose
beads. They were washed three times with ice-cold lysis
buffer, boiled in 2 sodium dodecyl sulfate (SDS) sample
buffer (125 mM Tris-HCl, pH 6.8; 10% 2-mercaptoethanol;
4% SDS; 20% glycerol; 0.01% bromophenol blue). Super-
natants were collected and subjected to SDS-PAGE. Proteins
were transferred to a polyvinylidene difluoride membrane,
which was blocked overnight at 4 C with 5% nonfat milk in
TTBS (TBS with 0.05% Tween 20). Blocking solution for
phosphotyrosine immunoblotting was 5% BSA in TTBS. In-
cubation with primary specific antibodies and horseradish
peroxidase-conjugated secondary antibodies was performed
in blocking solution for 1 h at room temperature. ECL de-
tected immunoreactive bands. Membrane stripping was per-
formed by incubating the membrane for 30 min at 50 C in
62.5 mM Tris-HCl (pH 6.7) containing 2% SDS and 100 mM
2-mercaptoethanol and extensively washing with TTBS at
room temperature. Stripping was checked by reexposure to
ECL, and membranes were subsequently blocked and re-
proved as described above.
Immune Complex Kinase Assay
Immunoprecipitates were first washed with 50 mM LiCl, 10
mM Tris-HCl (pH 7.4), 0.1 mM Na3VO4, then with TBS, 0.1 mM
Na3VO4, and finally with kinase buffer (20 mM Tris-HCl, pH
7.2, 10 mM MnCl2, 2 mM 2-mercaptoethanol). The immune
complexes of Fak, Src kinases, and Jak2 were resuspended
in 30 l of kinase buffer containing 5 Ci of [32P]--ATP (5000
Ci/mmol, 10 mCi/ml, Amersham) and incubated at 30 C for 5
min. Reactions were stopped by addition of 2 SDS sample
buffer and boiled for 3 min. The reaction mixtures were cen-
trifuged and the supernatants analyzed by SDS-PAGE. The
gels were subsequently dried and exposed to x-ray film to
visualize the 32P-labeled protein bands, or counted in an
Instantimager (Packard Instruments, Downers Grove, IL).
Proliferation Assays
Cell proliferation assays were determined by thymidine incor-
poration. Exponentially growing cells were plated in phenol
red-free DMEM-10% FCS into 24-well plates (5  104 cells
per well), rinsed twice with serum-free media 24 h later, and
cultured in this medium for 48 h. Cultures were then incu-
bated for 72 h in the absence or presence of PRL and/or PP1,
PD184352, or LY294002 dissolved in dimethylsulfoxide
(DMSO); control cultures were incubated with an equivalent
volume of DMSO (1:500 dilution). Each well was pulsed with
0.5 Ci of [3H]thymidine (48 Ci/mmol; Amersham Pharmacia
Biotech) for the final 4 h. Cells were trypsinized and harvested
onto glass fiber filter paper; the filters were dried and counted
in a solid scintillation counter (1450 Microbeta Wallac LKB,
Turku, Finland). All samples were assayed in triplicate.
[3H]Thymidine uptake of T47D and MCF7 unstimulated cells
(5  104 cells per well) was 12,280  1,283 cpm and
10,212  807 cpm (n  6), respectively.
Northern Blot Analysis
Total RNA was isolated using Tri Reagent. RNA was fraction-
ated by electrophoresis on 1% agarose gel containing 6%
formaldehyde and transferred to Nytran membranes (Schlei-
cher & Schuell, Dassel, Germany) by capillary blotting. Blots
were hybridized with cDNA probes labeled with the Oligola-
beling kit using 25 Ci -[32P]dCTP (3000 Ci/mmol; Amer-
sham Pharmacia Biotech). After several washes, the hybrid-
ization signals were visualized by autoradiography.
Statistical Analysis
Results were analyzed by Student’s t test. Differences be-
tween two means with a P  0.05 were regarded as signifi-
cant. All values were expressed as means  SE of at least
three experiments.
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